Literature DB >> 21972039

DAS28 and Rheumatoid Arthritis: The Need for Standardization.

Duncan Porter1, Kate Gadsby, Paul Thompson, Jo White, Catherine McClinton, Sue Oliver.   

Abstract

Disease Activity Score in 28 Joints (DAS28) scoring in rheumatoid arthritis (RA) is now recommended as a basis for clinical decisions about treatment initiation and alteration. The British Society of Rheumatology suggests that most RA patients should have a DAS28 assessment at every clinic visit, to monitor disease activity and the impact of therapy. Establishing an accurate baseline assessment of DAS28, with regular re-evaluation, is considered crucial, so that progress towards a defined target of remission (or low disease activity) can be measured. The Treat-to-Target initiative, launched in March 2010, is now impacting on clinical practice throughout the UK and Europe. One of its key recommendations is that patients should be regularly monitored using validated composite measures of disease activity that include joint assessments. DAS28 is recommended as one of the most useful of these methods but, although it is becoming more widely adopted and training is ongoing, supported by materials produced by the European League Against Rheumatism (EULAR), the variability inherent in the four components of DAS28 means that standardization of practice methods is now an important issue. This short report details some of the pitfalls that can occur when applying DAS28 in clinical practice and suggests some workable solutions to enable departments to set up their own standard operating procedure.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21972039     DOI: 10.1002/msc.218

Source DB:  PubMed          Journal:  Musculoskeletal Care        ISSN: 1478-2189


  4 in total

1.  Revising DAS28 scores for remission in rheumatoid arthritis.

Authors:  Claire Sheehy; Verity Evans; Heather Hasthorpe; Chetan Mukhtyar
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

2.  Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting.

Authors:  Saqa Ahmed; Tejal Magan; Mario Vargas; Abiola Harrison; Nidhi Sofat
Journal:  J Pain Res       Date:  2014-10-14       Impact factor: 3.133

3.  Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis.

Authors:  Catherine Cho; Anna Nguyen; Katherine J Bryant; Sean G O'Neill; H Patrick McNeil
Journal:  Immun Inflamm Dis       Date:  2015-11-25

4.  Efficacy and Safety of Qiwei Tongbi Oral Liquid in Patients with Stable Long-Standing Rheumatoid Arthritis.

Authors:  Wenjun Lu; Liping Fang; Jijie Zhang
Journal:  Biomed Res Int       Date:  2021-10-23       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.